Aytu Biopharma (AYTU) Other Non Operating Income (2015 - 2026)

Aytu Biopharma (AYTU) has reported Other Non Operating Income for 12 consecutive years, with -$1.3 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 155.59% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was -$4.4 million, a 158.45% decrease from a year earlier, with the FY2025 full-year figure at -$1.7 million, up 57.47% from the prior year.
• Other Non Operating Income was -$1.3 million for Q1 2026 at Aytu Biopharma, up from -$8.2 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $3.8 million in Q3 2025 and troughed at -$8.2 million in Q4 2025.
• A 5-year average of $239470.6 and a median of $1.3 million in 2025 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income surged 5577.5% in 2022 and sank 373.34% in 2025, its largest moves.
• Over 5 years, Other Non Operating Income stood at $1.4 million in 2022, then sank by 141.13% to -$577000.0 in 2023, then soared by 622.7% to $3.0 million in 2024, then slumped by 373.34% to -$8.2 million in 2025, then surged by 84.75% to -$1.3 million in 2026.
• The last three Other Non Operating Income figures came in at -$1.3 million (Q1 2026), -$8.2 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.